Lithium’s effect on bone mineral density
Bone. 2008 Oct 18. [Epub ahead of print] Zamani A, Omrani GR, Nasab MM. Lithium salts are widely used in treating psychiatric patients. Lithium may be associated with hyperparathyroidism, a risk factor for osteoporosis. However, the data on the effect of lithium on bone mass are conflicting. We assessed bone mineral density with dual-energy X-ray […]
Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84
Bone. 2008 Oct 17. [Epub ahead of print] Recker RR, Bare SP, Smith SY, Varela A, Miller MA, Morris SA, Fox J. Treatment with parathyroid hormone [PTH(1-84)] increases lumbar spine bone mineral density and decreases vertebral fractures, but its effects on bone microarchitecture are unknown. We obtained iliac crest biopsies from postmenopausal osteoporotic women given […]
Orthopaedic management improves the rate of early osteoporosis treatment after hip fracture. A randomized clinical trial
J Bone Joint Surg Am. 2008 Nov;90(11):2346-53. Miki RA, Oetgen ME, Kirk J, Insogna KL, Lindskog DM. BACKGROUND: Although osteoporosis is strongly associated with hip fractures, the initiation of osteoporosis treatment following hip fractures occurs at surprisingly low rates of between 5% and 30%. Currently, most patients receiving treatment have been referred back to their […]
Effect of alendronate in elderly patients after low trauma hip fracture repair
Osteoporos Int. 2008 Oct 28. [Epub ahead of print] Cecilia D, Jódar E, Fernández C, Resines C, Hawkins F. One year of once weekly alendronate, when given shortly after the surgical repair of a hip fracture, produces reductions in bone markers and increases proximal femoral bone density. The therapy was well tolerated. INTRODUCTION: Hip fracture […]
Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance
J Intern Med. 2008 Oct;264(4):315-32. Boonen S, Vanderschueren D, Venken K, Milisen K, Delforge M, Haentjens P. Bisphosphonates are the current mainstay of treatment for postmenopausal osteoporosis. Although daily oral dosing is effective, it is associated with poor compliance, partly because of the pre and postdose fasting and posture requirements. This negatively impacts treatment outcomes, […]
Pathogenesis and management of Paget’s disease of bone.
Lancet. 2008 Jul 12;372(9633):155-63. Ralston SH, Langston AL, Reid IR. Paget’s disease of bone is a common disease characterised by focal areas of increased bone turnover, affecting one or several bones throughout the skeleton. Paget’s disease is often asymptomatic but can be associated with bone pain and other complications such as osteoarthritis, pathological fracture, bone […]
Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling
NULL Bone. 2008 Jun 3. [Epub ahead of print] McDonald MM, Dulai S, Godfrey C, Amanat N, Sztynda T, Little DG. Orthopaedic Research and Biotechnology, The Children’s Hospital at Westmead, Westmead Australia; Science Department, University of Technology Sydney, Australia. INTRODUCTION: It has been widely assumed that osteoclasts play a pivotal role during the entire process […]
Changes of the quality-of-life under the treatment of severe senile osteoporosis with teriparatide
NULL Arch Gerontol Geriatr. 2008 Jun 12. [Epub ahead of print] Maugeri D, Russo E, Luca S, Carmelo L, Mamazza G, Sorace R, Rizzotto M, Manuele S, Fiore V, Taverna G, Biagio C, Calitro M. Despite being treated with antiresorptive drugs, the severe osteoporosis (SO) is being considered as a condition in which patients are […]
Use of alendronate and risk of incident atrial fibrillation in women
NULL Arch Intern Med. 2008 Apr 28;168(8):826-31 Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM. BACKGROUND: A recent publication from the HORIZON (Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly) trial in women with postmenopausal osteoporosis reported a higher risk of serious atrial fibrillation (AF) in zoledronic acid recipients than in […]
Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment
NULL Sebba AI. Clin Ther. 2008 Mar;30(3):443-52. Background: Oral bisphosphonates are routinely prescribed for the treatment of postmenopausal osteoporosis. In clinical trials, oral bisphosphonates have been found to increase bone mineral density (BMD) and decrease fracture risk in the majority of the treated population. However, in both clinical trials and clinical practice, not all patients […]
